Institute for International Research

Chairperson's Recap of Day One

Lance K. Gordon, PhD, President and CEO, Immunobiologics Corporation

Transition of a Device-Based Platform for DNA Vaccine Delivery into Clinical Testing

As illustrated in numerous studies in animal models, DNA vaccines have tremendous potential for generating robust, broad immune responses against antigens relevant to a range of indications, including infectious diseases, autoimmune disorders, and cancer. However, in the clinical setting DNA vaccines have thus far failed to promote immune responses at a magnitude and consistency sufficient for commercial product development. One key factor contributing to these results is the relative inefficiency in the uptake of DNA vaccines into cells. In vivo electroporation greatly enhances DNA delivery into cells and can increase the potency of DNA vaccines by up to 1000-fold in animal models compared to conventional methods of administration. The development of electroporation technology wherein the means for DNA vaccine administration and electric field application are integrated into a single, fully automated administration device has supported transition from animal models of electroporation-based DNA vaccine delivery into human clinical trials. §          Development of a clinical electroporation device§          Regulatory hurdles for a drug-device combination product§          Initiation of clinical trials§          Future prospects for electroporation-mediated delivery of DNA vaccines

Claire Evans, PhD, Director of Protein Therapies, Ichor Medical Systems

 Keynote Presentation The Patient Perspective with Five-Time NBA Champion and Business Leader Magic Johnson

Earvin ‘Magic' Johnson, NBA Champion, Chairman and CEO, JOHNSON DEVELOPMENT CORPORATION (JDC)

State of the Industry Address: Innovation In Science and Technology: A Critical Path to Addressing Global Health Inequities

Dr. Steven Buchsbaum, Senior Technology Strategy Officer, Bill & Melinda Gates Foundation

Use Aluminum-Containing Adjuvants Effectively For Improved Formulation and Stability

Stanley L. Hem, PhD, Professor, Purdue University

Achieve Enhanced Vaccine Immunogenicity Without Toxicity

Professor Nikolai Petrovsky MBBS, PhD, FRACP, Director of Endocrinology, Flinders Medical Centre and Vaxine

Panelists:

Lance K. Gordon, PhD, President and CEO, ImmunoBiologics Corporation

Professor Nikolai Petrovsky MBBS, PhD, FRACP, Director of Endocrinology, Flinders Medical Centre and Vaxine